Skip to main content

Epstein Robert S's Form 4 filing

Veracyte, Inc.VCYT · filed Oct 3, 2025

Accession no.
0001252004-25-000005
Filed
Oct 3, 2025
Trade date
Oct 1, 2025
Filing delay
2 days
Rule 10b5-1 plan
Checked

This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $753.3K. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Epstein Robert SCIK 0001252004Director

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Oct 1, 2025Common StockMOption exerciseAcquired+10,000$7.94+$79,40083,919Direct
Oct 1, 2025Common StockSSaleDisposed−21,473$35.08F2−$753,272.8462,446Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Oct 1, 2025Common StockMOption exerciseDisposed−10,000$0.00$00Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

Represents weighted average sales price. Sale prices for the transactions range from $35.00 to $35.30. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)